Fig. 7: Antitumour effect of SR9243 in vivo. | Cell Death & Disease

Fig. 7: Antitumour effect of SR9243 in vivo.

From: Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?

Fig. 7: Antitumour effect of SR9243 in vivo.

a Nude mice were treated with normal saline (n = 8) or 60 mg/kg (n = 8) SR9243 via intraperitoneal injection for 42 days, and photographs of the tumours were obtained at autopsy. b Scatter plot analysis of tumour weights in nude mice. c Tumour volume was measured every 3 days. All data are expressed as the mean ± S.E.M. d The body weight of nude mice was measured every 3 days. The image shows the effect of SR9243 on the body weight of tumour-bearing nude mice. e IHC was used to detect differences in FASN, SCD1 and SREBP-1c expression between the two tumour groups. Scale bar: 50 µm. f IHC staining score for each protein (e) in the two groups. The data are expressed as the mean ± S.E.M. g CHOL, TRIG, LDL and HDL levels in the two groups. h, i Plasma levels of ALP, AST, ALB, ALT, CREA and BUN in the two groups

Back to article page